Simplify Propel Opportunities ETF Rating $16.54 +0.05 (+0.30%) (As of 12/20/2024 04:33 PM ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Simplify Propel Opportunities ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.SURI Aggregate RatingModerate Buy 2.59Holdings in SURI have an aggregate rating of Moderate Buy based on 131 analyst ratings issued in the past year covering 17 companies (94.2% of the portfolio).SURI Aggregate Price Target$16.54High Prediction$16.54Average Prediction$16.54Low Prediction$16.54Holdings in SURI have an aggregate price target of $16.54 and a range of $16.54 to $16.54 covering 17 companies (94.2% of the portfolio).SURI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy8 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Simplify Propel Opportunities ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 17 SURI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings29.91%PAGPPlains GP$18.20+0.7%1.7483 of 5 stars2.11$19.88 9.2%9Analyst Downgrade8.97%MDGLMadrigal Pharmaceuticals$308.44+5.1%4.2404 of 5 stars2.69$347.33 12.6%13Positive News8.53%AKROAkero Therapeutics$29.34+3.3%4.09 of 5 stars2.88$46.83 59.6%8Insider Trade8.21%CASHPathward Financial$73.62-0.6%2.9321 of 5 stars2.50$86.00 16.8%2Positive NewsHigh Trading Volume5.74%RNAAvidity Biosciences$31.82+2.5%2.1835 of 5 stars3.00$64.36 102.3%11Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading Volume5.64%TCRXTScan Therapeutics$2.97+1.4%2.1808 of 5 stars3.00$11.25 278.8%4High Trading Volume5.64%PHATPhathom Pharmaceuticals$7.45-4.7%2.9846 of 5 stars2.75$23.00 208.7%4Gap UpHigh Trading Volume4.73%ARDXArdelyx$4.82+2.8%3.6947 of 5 stars2.88$10.42 116.1%84.33%APLTApplied Therapeutics$0.88-13.7%4.5346 of 5 stars2.86$6.10 593.1%7Analyst ForecastNews CoverageGap DownHigh Trading Volume2.96%ABEOAbeona Therapeutics$5.70+1.2%3.5974 of 5 stars3.00$18.00 215.8%3Analyst Upgrade2.45%SNDXSyndax Pharmaceuticals$13.08+1.8%3.9473 of 5 stars2.90$36.90 182.1%10News CoverageHigh Trading Volume1.71%KYMRKymera Therapeutics$40.66+3.9%2.2647 of 5 stars2.83$53.88 32.5%18Positive News1.32%ZVRAZevra Therapeutics$8.49-0.6%2.9065 of 5 stars3.13$21.00 147.3%8High Trading Volume1.18%ACHVAchieve Life Sciences$3.69-3.4%2.0087 of 5 stars3.33$14.80 301.1%6Positive NewsHigh Trading Volume1.14%ATHAAthira Pharma$0.58+5.1%2.1057 of 5 stars2.00$13.83 2,301.6%41.02%KURAKura Oncology$9.01+0.4%4.48 of 5 stars3.00$29.86 231.4%10High Trading Volume0.67%CMPSCOMPASS Pathways$3.97+1.3%2.8201 of 5 stars3.00$33.60 746.3%6Positive News This page (NYSEARCA:SURI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Simplify Propel Opportunities ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Simplify Propel Opportunities ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
